Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
about
25 Years of Proton Pump Inhibitors: A Comprehensive Review.Perforated peptic ulcerGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsAbsence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.A Five-Year Review of Perforated Peptic Ulcer Disease in Irrua, Nigeria.Gastric Hypersecretory States: Investigation and Management.Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndromeDiagnosis of Zollinger-Ellison syndrome: increasingly difficult.The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome.Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.Pharmacotherapy of Zollinger-Ellison syndrome.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Five-Year Long-Term Followup of a Primary Lymph node Gastrinoma: Is a Pancreaticoduodenectomy Justified?Surgical treatment of multiple spine metastases from gastrinoma.The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.Laparoscopic-assisted pancreaticoduodenectomy in a child with gastrinoma.CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradication
P2860
Q28070003-A499F530-6F14-46BE-AA97-87BCFAD77278Q28084426-AE7D2AB0-B3F0-4DE6-9C57-409FB7E52604Q28290833-FA2C9A50-EF48-4800-A0DA-F8CB8CB4C38BQ33338273-03A26E40-5FBD-46C7-9F40-BC6E0F194F03Q33800922-0EE3AACF-1273-49BE-9D6A-5F019FC40145Q36248833-D9220E78-E142-4AFD-ABA5-BD7E6B5DBC56Q36336998-AB603D59-E603-458F-A135-480036904FF1Q36351873-168F930B-606E-4DD7-AC1C-4DD8F11D1544Q36376405-CE9DF700-115D-49E5-8F0C-9B03780EEC6DQ36376528-DD59FF0A-7658-4652-9F45-F9ED862F7B3DQ36632665-7523EB94-FF43-4FEA-AD8F-B696DAAFD4FFQ37056120-752031CA-2315-4CC9-B887-2467FC0DEDBBQ42076259-9166C13F-72E3-4CE3-A645-5A845C0F8515Q42352980-08BA4582-4298-4DBA-8873-A05199B5A6EDQ47822235-8B256EF7-915E-4B47-84F9-70808F72B014Q50075239-75C53159-3F10-41D8-A268-BC47B3477EA0Q52986095-A7C8DE0A-4718-4089-8171-73E645278BA5Q56332424-A127D8D3-0768-4D63-98A4-ED2CF92491C5
P2860
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical outcome using lansopr ...... : a 13-year prospective study.
@en
Clinical outcome using lansopr ...... : a 13-year prospective study.
@nl
type
label
Clinical outcome using lansopr ...... : a 13-year prospective study.
@en
Clinical outcome using lansopr ...... : a 13-year prospective study.
@nl
prefLabel
Clinical outcome using lansopr ...... : a 13-year prospective study.
@en
Clinical outcome using lansopr ...... : a 13-year prospective study.
@nl
P2093
P1476
Clinical outcome using lansopr ...... : a 13-year prospective study.
@en
P2093
Basil I Hirschowitz
Jean Mohnen
Julie Simmons
P356
10.1016/S1542-3565(04)00606-8
P407
P577
2005-01-01T00:00:00Z